The results of a Phase I study assessing the safety, tolerability, and pharmacokinetic properties of SCY-247 were presented at ESCMID 2026.

The post ESCMID Global 2026: SCY-247 as novel invasive candidiasis therapy appeared first on Clinical Trials Arena.